Intravenous busulfan before autologous stem cell transplantation in children with cancer

被引：0
|
作者：
Le Guyader, N. [1 ]
Landre, T. [1 ]
Haouy, S. [1 ]
Landman-Parker, J. [1 ]
Fasola, S. [1 ]
Auvrignon, A. [1 ]
Leverger, G. [1 ]
机构：
[1] Hop Armand Trousseau, Paris, France
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S302 / S302
页数：1
相关论文
共 50 条
  • [31] Superior Survival in Non-Hodgkin Lymphoma Following Autologous Stem Cell Transplantation with Intravenous Busulfan, Cyclophosphamide, and Etoposide
    Dean, Robert
    Rybicki, Lisa
    Pohlman, Brad
    Sweetenham, John William
    Smith, Stephen
    Copelan, Edward
    Sobecks, Ronald
    Kalaycio, Matt
    Andresen, Steven
    Sungren, Shawnda
    Bolwell, Brian J.
    BLOOD, 2008, 112 (11) : 762 - 763
  • [32] Busulfan-based reduced-intensity regimen before allogeneic stem cell transplantation: tolerance of three days intravenous and fractionated busulfan
    Reman, O.
    Chantepie, S. P.
    Gac, A. C.
    Marin, E.
    Moreno, V.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S295 - S295
  • [33] Matched pair analysis comparing intravenous busulfan and oral busulfan as part of conditioning regimen in autologous stem cell transplantation in high-risk neuroblastoma
    Prete, A.
    Rondelli, R.
    Luksch, R.
    Fagioli, F.
    Morello, W.
    Castellini, C.
    Pession, A.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S292 - S292
  • [34] Comparison of melphalan together with busulfan or treosulfan as conditioning treatment before autologous stem cell transplantation in AML in first remission
    Gurevich, E.
    Hayoz, M.
    Aebi, Y.
    Largiader, C.
    Kronig, M. -N.
    Bacher, U.
    Pabst, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 44 - 44
  • [35] Intravenous busulfan decreases hepatic venoocclusive disease and overall 100-day mortality versus oral busulfan as part of conditioning regimen for autologous and allogeneic stem cell transplantation in children
    Molina, J. R.
    Gonzalez, M.
    Verdeguer, A.
    Martinez, A.
    Badell, I.
    Diaz, M. A.
    Maldonado, M.
    Gonzalez, E.
    Munoz, A.
    Gomez, P.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S290 - S291
  • [36] Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML
    Gurevich, Ekaterina
    Hayoz, Michael
    Aebi, Yolanda
    Largiader, Carlo R.
    Mansouri Taleghani, Behrouz
    Bacher, Ulrike
    Pabst, Thomas
    CANCERS, 2022, 14 (04)
  • [37] Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma
    Cogle, CR
    Moreb, JS
    Leather, HL
    Finiewicz, KJ
    Khan, SA
    Reddy, VS
    Wingard, JR
    AMERICAN JOURNAL OF HEMATOLOGY, 2003, 73 (03) : 169 - 175
  • [38] Once-daily intravenous busulfan versus oral busulfan in children prior to stem cell transplantation: study of pharmacokinetics and clinical outcomes
    Boelens, J. J.
    Bartelink, I.
    Bredius, R.
    Zwaveling, J.
    Bierings, M.
    Rademaker, K.
    Ververs, T.
    van Kesteren, C.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S12 - S12
  • [39] Once-daily intravenous Busulfan versus oral Busulfan in children prior to stem cell transplantation: Study of pharmacokinetics and clinical outcomes
    Boelens, J. J.
    Bartelink, I.
    Bredius, R.
    Zwaveling, J.
    Bierings, M.
    Rademaker, K.
    Ververs, T.
    Kesteren, C. van
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 58 - 59
  • [40] Busulfan,cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma
    张春阳
    China Medical Abstracts(Internal Medicine), 2013, 30 (02) : 116 - 117
12345